BrainScope announced that it is preparing for the introduction of the Ahead EU-100, a product in development to aid in the assessment of head injury, in the United Kingdom. This product has the potential to represent a significant advancement in the early identification and assessment of patients with traumatic brain injury.
This announcement coincides with BrainScope’s recent statement that it is entering the UK market with its B-Ahead UK clinical trial, a multicentre, observational clinical study utilising its technology in development to aid in the assessment of traumatic brain injury in emergency departments in the UK.
The Ahead EU-100 is a portable, non-invasive, point of care, non-radiation emitting medical device in development that utilises product miniaturisation and advanced signal processing methods to provide an objective assessment and categorisation of brain electrical activity associated with brain injury, identifying patterns consistent with a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury.
The Ahead EU-100 consists of three main components: a hand-held device that includes software and algorithms for EEG acquisition and analysis and patient stratification, a disposable electrode headset, and a web-based capability for centralised storage and review of patient data.
“We are excited about the prospect of bringing this much needed product in development to the UK market,” said Michael Singer, CEO of BrainScope. “We have been fortunate to have the opportunity to collaborate with top UK hospitals and renowned clinical and scientific thought leaders to conduct our UK-based research. With approximately one million people each year attending the accident and emergency department in the UK following head injuries, we believe that the commercialisation of this product in the UK will provide a valuable tool for clinicians in making informed decisions for triage, treatment and care of patients with suspected head injuries.”
In conjunction with the launch of the B-Ahead UK clinical trial in late spring, the company anticipates obtaining CE mark certification in the second half of 2011 for European commercialisation.
In addition, BrainScope recently formed a UK subsidiary, BrainScope UK Ltd, representing the first subsidiary set up to commercialise its products outside of the United States. Also, in February 2011, the UK Intellectual Property Office granted registration of the BrainScope trademark.
BrainScope has been working with two prominent UK groups to navigate the UK health system and successfully establish a presence in the UK. Think London, London’s official foreign direct investment agency, has provided support to help BrainScope set up a UK-based office. UK Trade & Investment, the international development agency for the British Government, provided valuable assistance to BrainScope, enabling them to understand the healthcare landscape and guide the company through upcoming healthcare reform in the UK.
Nick McInnes, director of UK Trade & Investment USA said, “It has been a pleasure to work with BrainScope and help them establish their presence in the UK. This novel product has the potential to fulfill many public health needs. We are thrilled that such an innovative healthcare company has selected the UK to set up its international operations, providing a springboard for future growth prospects throughout the rest of Europe.”